Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled,
proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1)
administered with food for 16 weeks in subjects with DLB. The primary objective is to
evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific
Cogstate Neuropsychological Test Battery (NTB). Secondary endpoints include the Clinical
Dementia Rating Scale-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE),
Neuropsychiatric Inventory (NPI-10), Timed Up and Go Test, and electroencephalogram (EEG) as
a potential biomarker for DLB.